Sandoz Group (SDZ) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Market position and performance

• Operates in a $200 billion market with 7% growth and nearly $10 billion in 2023 sales, holding a top-three global position and leading in Europe.

• Sandoz is a top 3 player in 90% of European markets and holds the #1 global position in biosimilars, with 28 biosimilars in development.

• Maintains 80% small molecule coverage in Europe and targets 60% of biosimilar loss-of-exclusivity (LOE) value.

• Launched key products like Hyrimoz, Ustekinumab, Tyruko, and Pyzchiva, achieving strong market shares and outperforming competitors.

• Expanded U.S. business, stabilized operations, and raised top-line guidance twice in 2023.

Pipeline, launches, and innovation

• Holds a robust pipeline with 28 biologics, adding two new assets annually, and 19 products in early-stage development.

• Plans significant launches in the U.S. and Europe, including Ustekinumab, Denosumab, Aflibercept, Erelzi, Tyruko, Wyost/Jubbonti, Enzeevu/Afqlir, and Pyzchiva.

• Focuses on GLP-1s, with initial launches in Canada and emerging markets from 2026, and broader opportunities in the 2030s.

• Invests in manufacturing, especially in Slovenia, to support future demand and maintain supply flexibility.

• Leverages partnerships with companies like Polpharma, Samsung, and Just Evotec for manufacturing and technology.

Operational efficiency and financial strategy

• Undertook a transformation post-separation, reducing network to 15 sites and consolidating suppliers for efficiency.

• Achieved $50 million in cost savings, targeting $200 million by 2026 through operational improvements and internal manufacturing simplification.

• Aims for mid-single-digit sales growth and margin expansion from 18% to 24–26% by 2028.

• Plans up to $200 million extra annual CapEx for infrastructure, with incremental R&D investment to fuel growth.

• Maintains a strong balance sheet with less than 2x net debt to core EBITDA and investment-grade rating.